SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001079973-21-000150
Filing Date
2021-03-05
Accepted
2021-03-05 16:13:31
Documents
1

Document Format Files

Seq Description Document Type Size
1 l1cap_scd13g.htm SC 13G 44551
  Complete submission text file 0001079973-21-000150.txt   46264
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Subject) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: SC 13G | Act: 34 | File No.: 005-92289 | Film No.: 21718630
SIC: 2834 Pharmaceutical Preparations

Mailing Address 161A SHEDDEN ROAD ONE ARTILLARY COURT P.O. BOX 10085 GRAND KAYMAN E9 KY1-1001
Business Address 161A SHEDDEN ROAD ONE ARTILLARY COURT P.O. BOX 10085 GRAND KAYMAN E9 KY1-1001 646-688-5654
L1 Capital Global Opportunities Master Fund, Ltd. (Filed by) CIK: 0001702202 (see all company filings)

IRS No.: 981241877 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13G